Abstract:The current study reported that combination of HER2 amplification and PD‐L1 expression in Chinese patients with gastric cancer could stratify the total populations into several subgroups with distinctive genomic and immune landscapes, which could be sensitive to different therapeutic regimens, indicating that both HER2 status and PD‐L1 expression level should be considered when making personalized treatment decisions for patients with advanced gastric cancer. Background Anti‐PD1/PD‐L1 antibody plus human epidermal growth factor receptor 2 (HER2) antibody and chemotherapy have become the new first‐line therapy for HER2 overexpression‐positive advanced gastric cancers (GC), suggesting that HER2 and PD‐L1 play a vital role in guiding systemic treatment for patients with GC. This study aimed to depict the genomic and immune landscapes of Chinese patients with GC and investigate their correlations with HER2 amplification and PD‐L1 expression. Patients and Methods Next‐generation targeted sequencing and PD‐L1 immunohistochemistry were performed on tumor samples from 735 patients with pathologically diagnosed GC. The genomic and immune landscapes and their correlations with HER2 amplification and PD‐L1 expression were analyzed. Results The most commonly mutated genes in Chinese GC were TP53 (64%), CDH1 (20%), ARID1A (18%), HMCN1 (15%), KMT2D (11%), and PIK3CA (11%). Seventy‐six (10%) patients were HER2 amplification, and 291 (40%) had positive PD‐L1 expression. Classifying the total population based on HER2 amplification and PD‐L1 expression level, 735 patients were divided into four subgroups: HER2+/PD‐L1+ (4.5%), HER2+/PD‐L1− (5.9%), HER2−/PD‐L1+ (35.1%), and HER2−/PD‐L1− (54.5%). The HER2+/PD‐L1− and HER2+/PD‐L1+ subgroups exhibited dramatically higher rate of TP53 mutations, CCNE1 and VEGF amplifications. The HER2+/PD‐L1− subgroup also had a markedly higher rate of MYC amplification and KRAS mutations. The HER2−/PD‐L1+ subgroup had significantly higher rate of PIK3CA mutations. HER2+/PD‐L1− subgroup had the highest TMB level and HER2−/PD‐L1+ subgroup had the highest proportion of patients with microsatellite instability‐high than other subgroups. Furthermore, we observed that different HER2 amplification levels had distinct impacts on the correlations between PD‐L1 expression and therapeutic genomic alterations, but no impact on the prognosis. Conclusion The combination of HER2 amplification and PD‐L1 expression in Chinese patients with GC could stratify the total populations into several subgroups with distinctive genomic and immune landscapes, which should be considered when making personalized treatment decisions.

Clinicopathological Features of Tumor Mutation Burden, Epstein-Barr Virus Infection, Microsatellite Instability and PD-L1 Status in Chinese Patients with Gastric Cancer

Clinic-pathological Features of Epstein-barr Virus Infection, Microsatellite Instability, Tumor Mutation Burden and PD-L1 Status in 2504 Chinese Gastric Cancer Patients

PD-L1 and Gastric Cancer Prognosis: A Systematic Review and Meta-Analysis

Cmar_a_206189 6397..6410

Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.

PD-L1 Expression is Associated with Massive Lymphocyte Infiltration and Histology in Gastric Cancer.

Microsatellite Instability and Epstein-Barr Virus Combined with PD-L1 Could Serve As a Potential Strategy for Predicting the Prognosis and Efficacy of Postoperative Chemotherapy in Gastric Cancer.

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

Molecular Profiles and Metastasis Markers in Chinese Patients with Gastric Carcinoma

Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing

Immunogenomic Classification of Gastric Cancer Based on the Tumor Microenvironments Expression of PD-L1 and CD8+T-cell Infiltration.

Integrated Assessment of PD-L1 Expression and Molecular Classification Facilitates Therapy Selection and Prognosis Prediction in Gastric Cancer

The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD‐L1 expression

Clinical and Genetic Characteristics of Early and Advanced Gastric Cancer

Somatic mutations that affect early genetic progression and immune microenvironment in gastric carcinoma

Tumor Mutation Burden And Immunogenicity In Gastric Cancer With Her2 Alterations.

[Clinicopathological and Molecular Characteristics of Epstein-Barr Virus Associated Gastric Cancer: a Single Center Large Sample Case Investigation].

Mutational Landscape of Gastric Adenocarcinoma in Chinese: Implications for Prognosis and Therapy.

Clinicopathological Features And Prognostic Value Of Mismatch Repair Protein Deficiency In Gastric Cancer

Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer

Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer